<DOC>
	<DOCNO>NCT00668863</DOCNO>
	<brief_summary>To evaluate efficacy , safety pharmacokinetics sunitinib plus FOLFIRI ( irinotecan , 5-FU l-leucovorin ) first-line treatment Japanese mCRC patient</brief_summary>
	<brief_title>Study Of Sunitinib With FOLFIRI In Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Patient histologically cytologicallyconfirmed colorectal adenocarcinoma unresectable metastatic disease document diagnostic imaging study . Patient must least one RECISTdefined measurable lesion treat prior local therapy . History another primary malignancy within 3 year prior study entry , exception nonmelanoma skin cancer situ carcinoma uterine cervix . Current , recent , planned participation experimental treatment drug study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>